Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings results on February 17, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.24, missing the consensus estimate of $2.15 by $2.39 per share. Revenue came in at $451.8M, beating the estimate of $447.1M.
Halozyme Therapeutics's stock moved following the earnings release. The stock currently trades at $75.04 with a market capitalization of $7.3B.